A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Condition:   Waldenstrom Macroglobulinemia Interventions:   Drug: Ibrutinib;   Drug: Rituximab Sponsor:   Janssen Pharmaceutical K.K. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials